Key result
High baseline plasma levels of tissue factor pathway inhibitor (>25.961 ng/mL) were significantly associated with reduced freedom from the need for aortic repair and MAAEs over 5 years (P=0.003).
Why the study?
Biomarkers predicting major adverse aortic events in abdominal aortic aneurysm are needed to risk-stratify patients for more rigorous medical treatment and potential earlier surgical intervention.
Are high baseline levels of TFPI associated with an increased risk of major adverse aortic events in patients with abdominal aortic aneurysm?
Cohort (n=268)
Are high baseline levels of TFPI associated with an increased risk of major adverse aortic events in patients with abdominal aortic aneurysm?
p-value: p=0.003
Elevated baseline TFPI levels (>25.961 ng/mL) may serve as a valuable prognostic biomarker for predicting major adverse aortic events and the need for aortic repair within 5 years in patients with abdominal aortic aneurysm.
Background: Abdominal aortic aneurysm (AAA) is characterized by the proteolytic breakdown of the extracellular matrix, leading to dilatation of the aorta and increased risk of rupture. Biomarkers that can predict major adverse aortic events (MAAEs) are needed to risk stratify patients for more rigorous medical treatment and potential earlier surgical intervention. Objectives: The primary objective was to identify the association between baseline levels of these biomarkers and MAAEs over a period of 5 years. Methods: Baseline levels of 3 proteases (matrix metalloproteinases 7, 8, and 10) and 3 protease inhibitors (tissue factor pathway inhibitor [TFPI], SerpinA12, SerpinB3) were investigated. Plasma levels of these biomarkers were quantified in 134 patients with AAA and 134 matched controls. Patients were followed for a 5-year period during which MAAEs were documented. The association between these markers and MAAEs was evaluated using Cox regression and Kaplan-Meier survival curves. Results: = .003) after adjusting for covariates. Kaplan-Meier survival analyses demonstrated that patients in the high TFPI group (defined as plasma levels >25.961 ng/mL) had significantly reduced freedom from the need for aortic repair and MAAEs. Conclusion: These findings suggest that TFPI may serve as a valuable prognostic marker for the risk of MAAEs within 5 years in patients with AAA, potentially offering new tools for the medical management of patients with AAA.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2024) conducted a cohort in Abdominal aortic aneurysm (n=268). High tissue factor pathway inhibitor (TFPI) levels (>25.961 ng/mL) vs. Low TFPI levels (≤25.961 ng/mL) was evaluated on Major adverse aortic events (MAAEs) (p=0.003). High baseline plasma levels of tissue factor pathway inhibitor (>25.961 ng/mL) were significantly associated with reduced freedom from the need for aortic repair and MAAEs over 5 years (P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: